Acriflavine |
| Catalog No.GC32083 |
L'acriflavine est un colorant fluorescent pour marquer l'ARN de haut poids moléculaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 8048-52-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic.
Acriflavine is identified as a potent inhibitor of the MCT4 that can inhibit the binding between Basigin and MCT4. Acriflavine significantly inhibits growth and self-renewal potential of several glioblastoma neurosphere lines[1]. The HIF-1 inhibitor acriflavine decreases survival and growth of CML cells. It targets stem cell potential of CML cells[2].
Acriflavine treatment inhibits intratumoral expression of VEGF and tumor vascularization[1]. In a murine CML model, acriflavine decreases leukemia development and reduces LSC maintenance[2]. Acriflavine retards tumor growth in a murine model of breast cancer. The combination of sunitinib with acriflavine significantly decreases vascular endothelial growth factor and TGF-β expression and reduces tumor vasculature followed by increased intratumor necrosis and apoptosis[3].
[1]. Voss DM, et al. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017 Jun 27;7(1):4292. [2]. Cheloni G, et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017 Jun 2. pii: blood-2016-10-745588. [3]. Yin T, et al. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model. Oncol Res. 2014;22(3):139-45.
Animal experiment: | Mice: CML mice are treated daily with acriflavine (8 mg/kg) or PBS via intraperitoneal injection, for 10 days starting from day 7 after bone marrow transplantation[2]. |
References: [1]. Voss DM, et al. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017 Jun 27;7(1):4292. | |
| Cas No. | 8048-52-0 | SDF | |
| Canonical SMILES | NC(C=C1)=CC(C1=C2)=NC3=C2C=CC(N)=C3.NC(C=C4)=CC(C4=C5)=[N+](C)C6=C5C=CC(N)=C6.[Cl-] | ||
| Formula | C14H14ClN3 | M.Wt | 259.73 |
| Solubility | Water : ≥ 25 mg/mL (96.25 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8502 mL | 19.2508 mL | 38.5015 mL |
| 5 mM | 0.77 mL | 3.8502 mL | 7.7003 mL |
| 10 mM | 0.385 mL | 1.9251 mL | 3.8502 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *